NSE ScannerComparison · NSE · data 2026-11-01
AstraZeneca Pharma India Limited vs Cohance Lifesciences Ltd
In plain words
Size: Cohance Lifesciences Ltd is about 1.1 times the market value of AstraZeneca Pharma India Limited.
Valuation (P/E): Cohance Lifesciences Ltd 161 vs AstraZeneca Pharma India Limited 93.8.
Return on equity: AstraZeneca Pharma India Limited 23.9% vs Cohance Lifesciences Ltd 6.4%.
Profit growth over 3 years: AstraZeneca Pharma India Limited 23.6% a year vs Cohance Lifesciences Ltd -24.2% a year.
Debt to equity: AstraZeneca Pharma India Limited 0.13 vs Cohance Lifesciences Ltd 0.1.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ASTRAZEN | COHANCE | |
|---|---|---|
| Price | ₹6,364.5 | ₹444.3 |
| Market cap | ₹15,918 cr | ₹17,005 cr |
| P/E | 93.8 | 161 |
| P/B | — | 4.4 |
| ROE | 23.9% | 6.4% |
| ROCE | 25.5% | 4.6% |
| Debt / equity | 0.13 | 0.1 |
| Operating margin | 9.9% | 5.8% |
| Dividend yield | 0.57% | 0.00% |
| Sales growth, 3 years (yearly) | 31.4% | 19.0% |
| Profit growth, 3 years (yearly) | 23.6% | -24.2% |
| 1-year return | -31.8% | -44.0% |
| Revenue, last 12 months | ₹2,432 cr | ₹2,142 cr |
| Net profit, last 12 months | ₹170 cr | ₹106 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹38 cr | ₹-24 cr |
| Quarter profit vs a year earlier | -32.1% | -149.3% |
| Promoter holding | 75.00% | 57.48% |
| Health check | Average (4.4/10) | Weak (2.2/10) |
Common questions
Which has a higher P/E, AstraZeneca Pharma India Limited or Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd trades at the higher P/E (161 against 93.8). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
AstraZeneca Pharma India Limited (23.9% against 6.4%).
Which carries more debt?
AstraZeneca Pharma India Limited has the higher debt-to-equity ratio (0.13 against 0.1).